Neuronal Ceroid Lipofuscinosis – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of neuronal ceroid lipofuscinosis (NCL) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of NCL for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.

Clarivate Epidemiology’s NCL forecast will answer the following question:

  • How will demographic trends, such as changes in birth rates and population size, affect the epidemiology of NCL over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology forecasts five NCL populations as follows:

  • Diagnosed prevalence of NCL.
  • Diagnosed prevalence of NCL 1.
  • Diagnosed prevalence of NCL 2.
  • Diagnosed prevalence of NCL 3.
  • Diagnosed prevalence of NCL 4.

Note: Coverage may vary by country.

launch Related Market Assessment Reports